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Opportunities to Improve the Efficacy and Safety of Oral Anticoagulant Therapy in Atrial 
Fibrillation—Insights from a Multistate Health Care System
Ty J. Gluckman, MD1, Amir Ali2, Callie Scott2, John L. Petersen II, MD3
Background
• Vitamin K antagonists (VKAs) effectively reduce thromboembolic risk in atrial 
fibrillation (AF), but are limited by a narrow therapeutic window1,2.
• Patients on VKAs with reduced time in the therapeutic range (TTR) face an increased 
risk of bleeding and ischemic events2.
• Based in part on this, current guidelines give preference to direct-acting oral 
anticoagulants (DOACs) over VKAs in AF3.
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Methods
• Cross-sectional analysis (August 1, 2018) of patients with AF from a multistate health 
care system.
• Electronic health record and coding (ICD-10) data was used to identify patients with 
AF, calculate their CHA2DS2-VASc score, and define their current antithrombotic 
regimen.
• Men with a CHA2DS2-VASc score <2 and women with a CHA2DS2-VASc score <3 
were excluded from the analysis.
• Demographics and comorbidities for 61,698 unique patients with AF on an OAC were 
assessed to allow for comparison between those receiving a VKA compared to a 
DOAC.
• The Rosendaal method was used to calculate TTR for 8,807 unique patients for whom 
sufficient INR values were available.
• Categorical variables were expressed as counts with percentages. Proportions of 
categorical variables were compared between groups by chi-square test or Fisher 
exact test, as appropriate. All significance tests were two tailed and a p value less than 
0.05 was considered statistically significant. Tukey method was used for post-hoc 
multiple comparisons testing when needed. 
• SAS version 9.4 (SAS Institute Inc.) was used for all analyses.
Conclusions
• In a contemporary, non-registry setting, VKAs continue to be used in nearly half of at-
risk patients on OAC therapy for AF.
• Among those treated with a VKA, a suboptimal TTR (<70%) is present nearly two 
thirds of the time.
• Further investigation is needed into tools that facilitate interchange from a VKA to a 
DOAC, particularly among those with a suboptimal TTR.
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Table 1 – Demographics. Counts with percentages of patients with AF overall, on a 
VKA or a DOAC with corresponding p values.
Objective
• Using real-world data from a large multistate health care system, we sought to 
evaluate a) the breakdown of OAC type and b) TTR for those on VKAs in an 
ambulatory population of at-risk AF patients.
AF = atrial fibrillation, DOAC = direct-acting oral anticoagulant, INR = international normalized ratio, OAC = oral anticoagulant, TTR = time in the therapeutic range, 
VKA = vitamin K antagonist
Figure 1 – Cohort selection flow diagram
Table 2 – Demographics. Counts with percentages of patients on a VKA with TTRs 
<70% and >70% with corresponding p values.
*407 patients on both a VKA and DOAC were excluded from the analysis
*
Variable Overall (n=61698) VKA (n=29513) DOAC (n=32185) p value
Age >65 years 58185 (94.3) 27903 (94.5) 30282 (94.1) 0.0143
Gender (n, % of male) 32730 (53.1) 16063 (54.4) 16667 (51.8) 0.0001
Race (n, %) 0.0001
American Indian or Alaska Native 377 (0.6) 173 (0.6) 204 (0.7)
Asian 1796 (3.0) 799 (2.8) 997 (3.2)
Black or African American 926 (1.5) 407 (1.4) 519 (1.7)
Native Hawaiian or Other Pacific 
Islander
199 (0.3) 110 (0.4) 89 (0.3)
Other 2320 (3.9) 960 (3.3) 1360 (4.3)
White or Caucasian 54565 (90.7) 26324 (91.5) 28241 (89.9)
Ethnicity (n, % Hispanic) 1807 (3.0) 720 (2.5) 1087 (3.4) 0.0001
Insurance 0.0001
Commercial 3486 (5.7) 1376 (4.7) 2110 (6.6)
Medicaid 800 (1.3) 350 (1.2) 450 (1.4)
Medicare 54581 (89.4) 26542 (90.9) 28039 (88.0)
Other 2180 (3.6) 919 (3.2) 1261 (4.0)
Hypertension (n, %) 38270 (62.0) 18552 (62.9) 19718 (61.3) 0.0001
Diabetes (n, %) 13324 (21.6) 7017 (23.8) 6307 (19.6) 0.0001
Coronary artery disease (n, %) 13234 (21.5) 6931 (23.5) 6303 (19.6) 0.0001
Myocardial infarction (n, %) 1896 (3.1) 943 (3.2) 953 (3.0) 0.09
Stroke or TIA (n, %) 7912 (12.8) 3830 (13.0) 4082 (12.7) 0.27
Peripheral vascular disease (n, %) 3953 (6.4) 2149 (7.3) 1804 (5.6) 0.0001
Heart failure (n, %) 11286 (18.3) 6477 (22.0) 4809 (14.9) 0.0001
Renal disease (n, %) 11373 (18.4) 6457 (21.9) 4916 (15.3) 0.0001
Liver disease (n, %) 982 (1.6) 515 (1.7) 467 (1.5) 0.0036
• Among AF patients on OAC therapy, men (54.4% vs. 51.8%, p=0.0001) and those 
with diabetes (23.8% vs. 19.6%, p=0.0001), coronary artery disease (23.5% vs. 
19.6%, p=0.0001), peripheral vascular disease (7.3% vs 5.6%, p=0.0001) and renal 
disease (21.9% vs. 15.3%, p=0.0001) were more likely to receive a VKA.




Figure 2 – Frequencies of TTR’s >50%, >60% and >70% for those on a VKA.
Percentage
Variable Overall (n=8094) TTR <70% (n=5293) TTR >70% (n=3314) p value
Age >65 years 8094 (94.0) 4937 (93.3) 3157 (95.3) 0.0001
Gender (n, % of male) 4521 (52.5) 2689 (50.8) 1832 (55.3) 0.0001
Race (n, %) 0.208
American Indian or Alaska Native 42 (0.5) 27 (0.5) 15 (0.5)
Asian 206 (2.4) 118 (2.3) 88 (2.7)
Black or African American 106 (1.3) 73 (1.4) 33 (1.0)
Native Hawaiian or Other Pacific 
Islander
25 (0.3) 15 (0.3) 10 (0.3)
Other 292 (3.5) 194 (3.7) 98 (3.0)
White or Caucasian 7791 (92.1) 4783 (91.8) 3008 (92.5)
Ethnicity (n, % hispanic) 267 (3.1) 174 (3.3) 93 (2.8) 0.2032
Insurance 0.65
Commercial 321 (3.7) 202 (3.8) 119 (3.6)
Medicaid 92 (1.1) 58 (1.1) 34 (1.0)
Medicare 7772 (90.6) 4760 (90.3) 3012 (91.1)
Other 395 (4.6) 253 (4.8) 142 (4.3)
Hypertension (n, %) 5609 (65.2) 3423 (64.7) 2186 (66.0) 0.2208
Diabetes (n, %) 2181 (25.3) 1401 (26.5) 780 (23.5) 0.0023
Coronary artery disease (n, %) 2074 (24.1) 1311 (24.8) 763 (23.0) 0.0655
Myocardial infarction (n, %) 233 (2.7) 154 (2.9) 79 (2.4) 0.1437
Stroke or TIA (n, %) 1110 (12.9) 693 (13.1) 417 (12.6) 0.49
Peripheral vascular disease (n, 
%)
685 (8.0) 454 (8.6) 231 (7.0) 0.0074
Heart failure (n, %) 1892 (22.0) 1208 (22.8) 684 (20.6) 0.0173
Renal disease (n, %) 1984 (23.1) 1284 (24.3) 700 (21.1) 0.0008
Liver disease (n, %) 177 (2.1) 115 (2.2) 62 (1.9) 0.337
• Among AF patients on a VKA, women (49.2% vs. 44.7%, p=0.0001) and those with 
diabetes (26.5% vs. 19.6%, p=0.0001), peripheral vascular disease (8.6% vs. 7.0%, 
p=0.0074), heart failure (22.8% vs 20.6%, p=0.0173) and renal disease (24.3% vs. 
21.1%, p=0.0008) were more likely to have a suboptimal TTR (<70%). 
Results (continued)
• Among AF patients on a VKA, the mean TTR was 56.3%, with 37.1%, 49.9% and 
60.8% with TTRs >70%, >60%, and >50%, respectively.
